Extracellular vesicle biomarkers for complement dysfunction in schizophrenia.
Xue T, Liu W, Wang L, Shi Y, Hu Y, Yang J, Li G, Huang H, Cui D.
Brain. 2024 Mar 1;147(3):1075-1086. doi: 10.1093/brain/awad341.
PMID:37816260
Risk Factors, Clinical Features, and Polygenic Risk Scores in Schizophrenia and Schizoaffective Disorder Depressive-Type.
Dennison CA, Legge SE, Hubbard L, Lynham AJ, Zammit S, Holmans P, Cardno AG, Owen MJ, O'Donovan MC, Walters JTR.
Schizophr Bull. 2021 Aug 21;47(5):1375-1384. doi: 10.1093/schbul/sbab036.
PMID:33837784
Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention.
Fusar-Poli P, Salazar de Pablo G, Correll CU, Meyer-Lindenberg A, Millan MJ, Borgwardt S, Galderisi S, Bechdolf A, Pfennig A, Kessing LV, van Amelsvoort T, Nieman DH, Domschke K, Krebs MO, Koutsouleris N, McGuire P, Do KQ, Arango C.
[Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].
Auxéméry Y.
Encephale. 2012 Oct;38(5):373-80. doi: 10.1016/j.encep.2011.12.003. Epub 2012 Jan 24.
PMID:23062450
What we know and what we don't know about the treatment of schizoaffective disorder.
Murru A, Pacchiarotti I, Nivoli AM, Grande I, Colom F, Vieta E.
Eur Neuropsychopharmacol. 2011 Sep;21(9):680-90. doi: 10.1016/j.euroneuro.2011.03.001. Epub 2011 May 12.
PMID:21565468
Pharmacologic treatment of schizoaffective disorder.